| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ab776b9caf951211029e64e07c6068a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaa8cf08e998b3ddf7927d943228bac9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b735f147a8c094f1c87c78a18cd69428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2e0ccb83f41f73e5a50061f1efe244f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4696c290989e178010aa1908bcbb526d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate |
2008-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3466354d20f74dbf9314703697c989b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46d49f52a329873b88e6714675afcdbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b2f33acd8763f9c18c3199d49185a38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c93a5e8d783078ae2c5f9082218e15b2 |
| publicationDate |
2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009022354-A3 |
| titleOfInvention |
Modified dosage forms of tacrolimus |
| abstract |
The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described. |
| priorityDate |
2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |